PBR Nachrichten

 

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen's Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Pharmaceutical Business review....

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger's computational platform for drug discovery projects. The new arrangement will extend The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review....

The funds will be used for AsymBio's principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will The post AsymBio to secure $184m to support growth in biologics manufacturing appeared first on Pharmaceutical Business review....

The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and The post Phylo and Chugai collaborate to deploy AI platform in drug discovery appeared first on Pharmaceutical Business review....

The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy. Olomorasib (LY3537982) is The post FDA grants breakthrough therapy designation to Lilly's olomorasib appeared first on Pharmaceutical Business review....

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus' shareholders The post Curium to acquire Lantheus in all-cash deal worth up to $8bn appeared first on Pharmaceutical Business review....

The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement, The post IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib appeared first on Pharmaceutical Business review....

The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and The post Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy appeared first on Pharmaceutical Business review....

The partnership is intended to jointly advance methods that address one of the main challenges for RNA medicines: delivering treatments to additional tissue types. While existing RNA therapies The post miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies appeared first on Pharmaceutical Business review....

The investment will support the expansion of Resilience's advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number The post Resilience and Lilly to increase US medicines production with $750m investment appeared first on Pharmaceutical Business review....

Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels, The post Amgen's Repatha receives positive CHMP opinion for broader cardiovascular use appeared first on Pharmaceutical Business review....

The companies will become 100%-owned subsidiaries of Caldera Therapeutics, a newly formed holding company. This combined company intends to apply for a listing on the Nasdaq Capital Market The post Synlogic and Caldera sign merger agreement appeared first on Pharmaceutical Business review....

Targeting long non-coding ribonucleic acid (lncRNA), HTX-001 is being evaluated in a Phase Ia/b clinical trial. The first cohort in this trial was dosed in May. This antisense The post FDA grants fast track designation for HAYA Therapeutics' HTX-001 appeared first on Pharmaceutical Business review....

The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting The post Eisai and CORE Biomedicine agree on global licence for oncology pipeline appeared first on Pharmaceutical Business review....

ReNU syndrome is a rare neurodevelopmental disorder that is caused by variants in the RNU4-2 gene. The agreement aims to address an estimated 75% of ReNU syndrome cases. The post BioMarin and n-Lorem partner on early research for ReNU syndrome therapy appeared first on Pharmaceutical Business review....

Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset involved The post argenx signs agreement to buy Forte Biosciences for $2.2bn appeared first on Pharmaceutical Business review....

This integrated service platform is designed to meet growing demand as computational methods increasingly generate large numbers of candidate antibody sequences in a single design cycle. However, the The post Biointron introduces RushData platform for AI-driven antibody discovery appeared first on Pharmaceutical Business review....

This combination aims to provide an additional non-opioid pain relief option without the need for prescriptions. The approval introduces a new choice for individuals seeking relief from persistent The post Kenvue's Tylenol with Naproxen gains FDA approval appeared first on Pharmaceutical Business review....

The new investment increases BeOne Medicines' total spend on US manufacturing facilities to exceed $1bn. This expansion will increase the company's production capacity for its cancer medicines and The post BeOne to invest $300m in US manufacturing facility expansion appeared first on Pharmaceutical Business review....

Lu AH69593 is an oral, small-molecule agonist of the orexin 2 receptor (OX2R). The compound is currently being studied in a Phase Ib clinical trial focused on patients The post FDA grants fast track designation for Lundbeck's Lu AH69593 appeared first on Pharmaceutical Business review....